up Data from IMPLANT2 Trial Echoing Favorable Safety Profile(2)
时间:2019-05-30 11:53 来源:百度新闻 作者:巧天工 点击:次
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol OBSN. For more information, please visit Cautionary Note Regarding Forward Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEvas current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEvas product candidates and the timing of enrollment in and data from clinical trials. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, clinical development and related interactions with regulators, ObsEvas reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEvas Annual Report on Form 20-F for the year ended December 31, 2018, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEvas website at Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please contact: Media Contact Switzerland and Europe: Christophe Lamps Dynamics Group cla@dynamicsgroup.ch +41 22 308 6220 Office +41 79 476 26 87 Mobile Media Contact U.S.: Marion Janic RooneyPartners LLC mjanic@rooneyco.com +1 212 223 4017 Office +1 646 537 5649 Mobile CEO Office Contact: Shauna Dillon Shauna.dillon@obseva.ch +41 22 552 1550 Investor Contact: Mario Corso Senior Director, Investor Relations mario.corso@obseva.com +1 857 972 9347 Office +1 781 366 5726 Mobile ### Attachment Press Release in Pdf (责任编辑：波少) |